Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Roots Analysis | PRODUCT CODE: 2037813

Cover Image

PUBLISHER: Roots Analysis | PRODUCT CODE: 2037813

Next Generation Immune Checkpoint Inhibitors Market (2nd Edition), by Target Immune Checkpoint, Target Disease Indication, Type of Molecule, Geographical Regions, Leading Players and Sales Forecast of Therapies - Trends and Forecast Till 2035

PUBLISHED:
PAGES: 285 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4799
PDF (One-Location Site License)
USD 6999
PDF (Department License)
USD 10599
PDF (Enterprise License)
USD 17999

Add to Cart

Description

Table of Contents

List of Tables

Next Generation Immune Checkpoint Inhibitors Market: Overview

As per Roots Analysis, the global next generation immune checkpoint inhibitors market is estimated to grow from USD 17.5 billion in the current year to USD 20.9 billion by 2035.

Next Generation Immune Checkpoint Inhibitors Market: Growth and Trends

Cancer remains a leading cause of mortality worldwide, and its increasing incidence across major geographies continues to underscore the urgent need for more durable and effective therapeutic solutions. While targeted therapies, chemotherapy, and radiation have delivered improved outcomes in certain clinical settings, many tumor types still exhibit limited or transient responses. First-generation immune checkpoint inhibitors (ICIs), particularly those targeting CTLA-4 and PD-1/PD-L1 pathways, have significantly transformed cancer treatment by enhancing antitumor immune activity; however, response rates remain inconsistent, and treatment resistance persists as a critical clinical challenge.

In response to these limitations, there is growing interest in next-generation immune checkpoint inhibitors (NGICIs). Novel targets, including LAG-3, TIM-3, TIGIT, CD47, VISTA, CD38, and adenosine receptors, are designed to address additional immune evasion mechanisms within the tumor microenvironment, thereby offering the potential for enhanced efficacy and expanded patient benefit. Backed by robust R&D pipelines, increasing clinical trial activity, and a rise in strategic industry collaborations, these innovations are driving significant commercial momentum and are expected to emerge as a key growth driver within the global immuno-oncology market.

Growth Drivers: Strategic Enablers of Market Expansion

The growing preference for modern immuno-oncology therapies is largely driven by the limitations of conventional cancer treatments and the rising global cancer burden. Traditional approaches such as chemotherapy and radiotherapy often face challenges related to toxicity, limited long-term efficacy, and reduced effectiveness in advanced disease due to tumor resistance. In contrast, immune checkpoint inhibitors offer a more targeted and durable treatment approach by activating the body's immune system, resulting in improved clinical outcomes and fewer systemic side effects.

This shift is further supported by the increasing incidence of cancer worldwide, with approximately 20 million new cases and over 10 million deaths reported in 2025. The expanding disease burden is intensifying the need for more effective therapies, positioning immuno-oncology treatments as a key solution. Backed by strong clinical performance and expanding approvals across multiple tumor types, these therapies continue to drive significant market adoption and investment.

Market Challenges: Critical Barriers Impeding Progress

The immune checkpoint inhibitor market continues to encounter notable constraints related to both patient selection and safety. A key challenge is the absence of robust and universally accepted biomarkers capable of accurately predicting patient response, resulting in the inclusion of non-responders in clinical trials and inefficient utilization of time and resources. Moreover, treatment efficacy is influenced by a complex interplay of biological factors, including tumor mutations, immune microenvironment, Human Leukocyte Antigen (HLA) profiles, microbiome composition, and patient genetics, limiting the effectiveness of single-marker approaches.

In addition, immune-related adverse events (irAEs) remain a significant safety concern, as enhanced immune activation can lead to unintended organ toxicities such as thyroiditis, colitis, and pneumonitis. In severe cases, these events may necessitate treatment interruption or immunosuppressive interventions, potentially impact clinical outcomes and increasing healthcare costs. Collectively, these challenges continue to pose barriers to broader adoption and optimal utilization of next-generation checkpoint inhibitors.

Next Generation Immune Checkpoint Inhibitors Market: Key Insights

The report delves into the current state of the next generation immune checkpoint inhibitors market and identifies potential growth opportunities within industry. Some key findings from the report include:

  • Driven by the need for overcoming acquired resistance to first generation therapies, along with the necessity to manage immune-related adverse events, companies are actively advancing their next generation immune checkpoint inhibitor pipelines.
  • The current immune checkpoint inhibitor pipeline features ~475 therapy programs, emphasizing on enhanced pathway modulation to deliver sustained therapeutic benefit in the oncology domain.
Next Generation Immune Checkpoint Inhibitors Market - IMG1
  • 45% of the immune checkpoint inhibitors are in phase II of clinical trials, reflecting the maturity of the current pipeline, which is influenced by the positive study trial outcomes of ICIs in early stages of clinical development.
  • The current next generation immune checkpoint inhibitor pipeline features ~150 therapy programs, facilitating enhanced cancer treatment by ensuring targeted drug delivery and reduced off target effects.
  • >40% of NGICIs are being evaluated in combination therapy (including radiation, chemotherapy and targeted therapies), highlighting the shift toward regimens that improve antitumor response and enhance clinical outcomes.
Next Generation Immune Checkpoint Inhibitors Market - IMG2
  • Majority of the trials (nearly 30%) were registered in the last two years; >50% of the clinical trials in NGICIs domain are being conducted by industry players, highlighting their active role in driving innovation in this segment.
  • The next generation immune checkpoint inhibitors market is experiencing significant growth, owing to the rise in the incidence of cancer, worldwide, demanding advanced targeted treatment approaches.
Next Generation Immune Checkpoint Inhibitors Market - IMG3
  • Given the rapid increase in popularity of immune checkpoint inhibitors, the market is poised to grow at a CAGR of 30% till 2035 (excluding Darzalex); CD38 targeting therapies currently capture majority of NGICIs market share.
  • The immune checkpoint inhibitors market in the US is expected to grow at a steady CAGR during the forecast period due to their enhanced selectivity and expanding clinical use for the treatment of oncological disorders.
  • Driven by expanding clinical use and growing adoption of immunotherapies, the next generation immune checkpoint inhibitors market in the US expected to witness sustained progress.

Next Generation Immune Checkpoint Inhibitors Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Target Immune Checkpoint

  • C CD38
  • B7-H3
  • TIGIT
  • LAG-3
  • CD73

By Target Disease Indication

  • Multiple Myeloma
  • Lung Cancer
  • Melanoma
  • Light Chain Amyloidosis
  • Immune Thrombocytopenia
  • Prostate Cancer
  • Esophageal Cancer
  • Pancreatic Cancer

By Type of Molecule

  • Biologics
  • Small Molecules

By Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and North Africa

By Leading Players

  • Leading Player 1
  • Leading Player 2
  • Leading Player 3
  • Leading Player 4
  • Leading Player 5

By Sales Forecast of Therapies

  • Darzalex
  • Sarclisa
  • ONO-4882
  • Ifinatamab Deruxtecan / MK-2400
  • GSK5764227
  • Mezagitamab (TAK-079)
  • Fianlimab
  • Quemliclustat
  • Domvanalimab

Next Generation Immune Checkpoint Inhibitors Market: Key Segments

Target-Based Segmentation: Market Share Insights

The next-generation immune checkpoint inhibitors market is broadly distributed across multiple targets, including CD38, B7-H3, TIGIT, LAG-3, and CD73. By 2035, the CD38 segment is expected to dominate the market, accounting for over 50% of the overall share. Meanwhile, the B7-H3 segment is projected to register the fastest growth during the forecast period. This growth is driven by the unique dual functionality of B7-H3, which can exert both stimulatory and immunosuppressive effects on the immune system, with clinical evidence indicating a predominance of immunosuppressive activity, particularly in glioblastoma. These attributes position B7-H3 as a highly promising target for ongoing and future clinical development.

Type of Molecule Analysis: Market Leadership and Growth Trends

Based on the type of molecule, the market is segmented into biologics and small molecules. Biologics are anticipated to capture the largest share, accounting for nearly 95% of the market by 2035, primarily due to their high target specificity, reduced dosing frequency, and lower incidence of off-target effects, which collectively enhance patient compliance. Conversely, small molecules are expected to witness a higher CAGR over the forecast period, supported by their ability to modulate multiple anti-tumor pathways simultaneously, along with advantages such as oral bioavailability and low immunogenicity. These factors contribute to greater clinical flexibility, improved patient convenience, and increasing commercial attractiveness.

Regional Analysis: Growth and Market Expansion

North America is projected to remain the dominant regional market, capturing over 60% of the global share by 2035, supported by its advanced healthcare infrastructure, strong research capabilities, and well-established regulatory framework that facilitates extensive clinical development. In contrast, Asia-Pacific and the Rest of the World are expected to experience the fastest growth during the forecast period. This growth is driven by a large and expanding cancer patient population, particularly in Southeast Asia, coupled with a rising disease burden and a rapidly evolving clinical research ecosystem. These factors are anticipated to significantly increase the demand for next-generation immune checkpoint inhibitor therapies across these regions.

Example Players in Next Generation Immune Checkpoint Inhibitors Market

  • Arcus Biosciences
  • Aurigene Oncology
  • Genetech
  • GlaxoSmithKline
  • Johnson and Johnson
  • Merck
  • NovaBridge Biotherapeutics
  • ONO Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Sanofi
  • Takeda

Next Generation Immune Checkpoint Inhibitors Market: Research Coverage

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the next generation immune checkpoint inhibitors market, focusing on key market segments, including [A] target immune checkpoint, [B] target disease indication, [C] type of molecule [D] geographical regions, [E] leading players, [F] and sales forecast of therapies.
  • Immune Checkpoint Inhibitors Market Landscape: A detailed assessment of the overall landscape of immune checkpoint inhibitors, along with information on several relevant parameters, such as [A] target immune checkpoint, [B] stage of development, [C] therapeutic modality, [D] route of administration, [E] target disease indication, [F] therapeutic area, [G] year of establishment, [H] company size and [I] location of headquarters.
  • Next Generation Immune Checkpoint Inhibitors Market Landscape: A detailed assessment of the overall landscape of immune checkpoint inhibitors market landscape, along with information on several relevant parameters, such as [A] target immune checkpoint, [B] stage of development, [C] therapeutic modality, [D] route of administration, [E] target disease indication, [F] therapeutic area, [G] year of establishment, [H] company size and [I] location of headquarters.
  • Target Competitiveness Analysis: An insightful competitiveness analysis of next generation immune checkpoint targets, based on various relevant parameters, such as [A] number of therapies, [B] number of unique target indications, [C] pipeline maturity, [D] highest phase of development, [E] number of clinical trials, [F] number of unique big pharma and start-ups / small sized companies involved.
  • Clinical Trial Analysis: An in-depth analysis of completed and ongoing clinical trials investigating next generation immune checkpoint inhibitor therapies, based on several relevant parameters, such as [A] trial registration year, [B] trial status, [C] trial phase, [D] patients enrolled, [E] trial study design, [F] type of sponsor, [G] patient gender, [H] most active industry and non-industry players (in terms of number of trials) and [I] geographical distribution.
  • Company Profiles: In-depth profiles of key companies based in North America, Europe and Asia-Pacific based on several parameters such as [A] year of establishment, [B] location of headquarters, [C] drug portfolio, [D] recent developments and [E] an informed future outlook.
  • Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of the market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges in this domain.

Key Questions Answered in this Report

  • Which are the leading companies in the next generation immune checkpoint market?
  • Which region dominates the next generation immune checkpoint market?
  • What are the key trends observed in the next generation immune checkpoint market?
  • What factors are likely to influence the evolution of this market?
  • What are the primary challenges faced by next generation immune checkpoint developers?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
  • The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
  • The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
  • The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
  • The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

  • Complementary PPT Insights Pack
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older
Show more
Product Code: RA100629

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Developers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. ECONOMIC AND OTHER PROJECT-SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Major Currencies Affecting the Market
      • 4.2.2.2. Factors Affecting Currency Fluctuations
      • 4.2.2.3. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Currency Exchange Rate
      • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
      • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
    • 4.2.6. Interest Rates
      • 4.2.6.1. Interest Rates and Their Impact on the Market
      • 4.2.6.2. Strategies for Managing Interest Rate Risk
    • 4.2.7. Commodity Flow Analysis
      • 4.2.7.1. Type of Commodity
      • 4.2.7.2. Origins and Destinations
      • 4.2.7.3. Value and Weights
      • 4.2.7.4. Modes of Transportation
    • 4.2.8. Global Trade Dynamics
      • 4.2.8.1. Import Scenario
      • 4.2.8.2. Export Scenario
      • 4.2.8.3. Trade Policies
      • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
      • 4.2.8.5. Impact of Trade Barriers on the Market
    • 4.2.9. War Impact Analysis
      • 4.2.9.1. Russian-Ukraine War
      • 4.2.9.2. Israel-Hamas War
    • 4.2.10. COVID Impact / Related Factors
      • 4.2.10.1. Global Economic Impact
      • 4.2.10.2. Industry-specific Impact
      • 4.2.10.3. Government Response and Stimulus Measures
      • 4.2.10.4. Future Outlook and Adaptation Strategies
    • 4.2.11. Other Indicators
      • 4.2.11.1. Fiscal Policy
      • 4.2.11.2. Consumer Spending
      • 4.2.11.3. Gross Domestic Product (GDP)
      • 4.2.11.4. Employment
      • 4.2.11.5. Taxes
      • 4.2.11.6. Stock Market Performance
      • 4.2.11.7. Cross-Border Dynamics
  • 4.3. Conclusion

5. EXECUTIVE SUMMARY

  • 5.1. Immune Checkpoint Inhibitors: Market Landscape
  • 5.2. Immune Checkpoint Inhibitors: Market Trends
  • 5.3. Immune Checkpoint Inhibitors: Market Forecast and Opportunity Analysis

6. INTRODUCTION

  • 6.1. Chapter Overview
  • 6.2. Introduction to Cancer Immunotherapy
  • 6.3. Fundamentals of Cancer Immunotherapy
  • 6.4. Immune Checkpoint Inhibitors
  • 6.5. First Generation Immune Checkpoint Modulators
  • 6.6. Next Generation Immune Checkpoint Modulators
    • 6.6.1. Types of Next Generation Modulators
  • 6.7. Challenges Related to Immune Checkpoint Inhibitors
  • 6.8. Future Perspective

7. MARKET LANDSCAPE: IMMUNE CHECKPOINT INHIBITORS

  • 7.1. Chapter Overview
  • 7.2. Immune Checkpoint Inhibitors: Overall Market Landscape
    • 7.2.1. Analysis by Stage of Development
    • 7.2.2. Analysis by Target Immune Checkpoint
    • 7.2.3. Analysis by Therapeutic Modality
    • 7.2.4. Analysis by Route of Administration
    • 7.2.5. Analysis by Target Disease Indication
    • 7.2.6. Analysis by Therapeutic Area
    • 7.2.7. Analysis by Popular Oncological Indications and Target Immune Checkpoints
    • 7.2.8. Analysis by Popular Non-Oncological Indications and Target Immune Checkpoints
  • 7.3. Immune Checkpoint Inhibitors: Developer Landscape
    • 7.3.1. Analysis by Year of Establishment
    • 7.3.2. Analysis by Company Size
    • 7.3.3. Analysis by Location of Headquarters
    • 7.3.4. Analysis by Company Size and Location of Headquarters
    • 7.3.5. Most Active Players: Analysis by Number of Immune Checkpoint Inhibitors Developed
    • 7.3.6. Prominent First Generation Targets: Distribution by Number of Developers

8. MARKET LANDSCAPE: NEXT GENERATION IMMUNE CHECKPOINT INHIBITORS

  • 8.1. Chapter Overview
  • 8.2. Next Generation Immune Checkpoint Inhibitors: Overall Market Landscape
    • 8.2.1. Analysis by Stage of Development
    • 8.2.2. Analysis by Target Immune Checkpoint
    • 8.2.3. Analysis by Therapeutic Modality
    • 8.2.4. Analysis by Route of Administration
    • 8.2.5. Analysis by Target Disease Indication
    • 8.2.6. Analysis by Therapeutic Area
    • 8.2.7. Analysis by Popular Oncological Indications and Popular Target Immune Checkpoint
    • 8.2.8. Analysis by Popular Non-Oncological Indications and Target Immune Checkpoint
  • 8.3. Next Generation Immune Checkpoint Inhibitors: Developer Landscape
    • 8.3.1. Analysis by Year of Establishment
    • 8.3.2. Analysis by Company Size
    • 8.3.3. Analysis by Location of Headquarters
    • 8.3.4. Analysis by Company Size and Location of Headquarters
    • 8.3.5. Most Active Players: Analysis by Number of Immune Checkpoint Inhibitors Developed
    • 8.3.6. Prominent Next Generation Targets: Distribution by Number of Developers

9. TARGET COMPETITIVENESS ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Key Parameters
  • 9.4. Target Competitiveness Analysis: Key Targets for Next Generation Immune Checkpoint Inhibitors
    • 9.4.1. Target Competitiveness Analysis: 3D Bubble Analysis
    • 9.4.2. Target Competitiveness Analysis: Spider Web Analysis

10. CLINICAL TRIAL ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Immune Checkpoint Inhibitors: Clinical Trial Analysis
    • 10.3.1. Analysis by Trial Registration Year
    • 10.3.2. Analysis by Trial Status
    • 10.3.3. Analysis by Trial Registration Year and Trial Status
    • 10.3.4. Analysis by Trial Registration Year and Patients Enrolled
    • 10.3.5. Analysis by Trial Status and Patients Enrolled
    • 10.3.6. Analysis by Trial Phase
    • 10.3.7. Analysis by Patients Enrolled and Trial Phase
    • 10.3.8. Analysis by Study Design
    • 10.3.9. Analysis by Type of Sponsor
    • 10.3.10. Analysis by Patient Gender
    • 10.3.11. Most Active Industry Players: Analysis by Number of Trials
    • 10.3.12. Most Active Non-Industry Players: Analysis by Number of Trials
    • 10.3.13. Analysis by Geography
      • 10.3.13.1. Analysis by Trial Status, Trial Phase and Geography
      • 10.3.13.2. Analysis by Trial Status and Geography
    • 10.3.14. Geographical Distribution of Trials and Number of Patients Enrolled

11. COMPANY PROFILES: NEXT GENERATION IMMUNE CHECKPOINT INHIBITOR DEVELOPERS

  • 11.1. Chapter Overview
  • 11.2. Immune Checkpoint Inhibitors Offered by Drug Developers Based in North America
    • 11.2.1. Arcus
      • 11.2.1.1. Company Overview
      • 11.2.1.2. Next Generation Immune Checkpoint Therapeutics Portfolio
        • 11.2.1.2.1. Domvanalimab
        • 11.2.1.2.2. Quemliclustat
      • 11.2.1.3. Recent Developments and Future Outlook
    • 11.2.2. Genentech
      • 11.2.2.1. Company Overview
      • 11.2.2.2. Next Generation Immune Checkpoint Therapeutics Portfolio
        • 11.2.2.2.1. Tiragolumab
      • 11.2.2.3. Recent Developments and Future Outlook
    • 11.2.3. Johnson & Johnson
      • 11.2.3.1. Company Overview
      • 11.2.3.2. Next Generation Immune Checkpoint Therapeutics Portfolio
        • 11.2.3.2.1. Daratumumab
      • 11.2.3.3. Recent Developments and Future Outlook
    • 11.2.4. Merck
      • 11.2.4.1. Company Overview
      • 11.2.4.2. Next Generation Immune Checkpoint Therapeutics Portfolio
        • 11.2.4.2.1. Ifinatamab Deruxtecan
      • 11.2.4.3. Recent Developments and Future Outlook
    • 11.2.5. NovaBridge Biosciences
      • 11.2.5.1. Company Overview
      • 11.2.5.2. Next Generation Immune Checkpoint Therapeutics Portfolio
        • 11.2.5.2.1. Uliledlimab
      • 11.2.5.3. Recent Developments and Future Outlook
    • 11.2.6. Regeneron Pharmaceuticals
      • 11.2.6.1. Company Overview
      • 11.2.6.2. Next Generation Immune Checkpoint Therapeutics Portfolio
        • 11.2.6.2.1. FIANLIMAB
      • 11.2.6.3. Recent Developments and Future Outlook
  • 11.3. Immune Checkpoint Inhibitors Offered by Drug Developers Based in Europe
    • 11.3.1. GlaxoSmithKline
      • 11.3.1.1. Company Overview
      • 11.3.1.2. Next Generation Immune Checkpoint Therapeutics Portfolio
        • 11.3.1.2.1. GSK5764227
        • 11.3.1.2.2. GSK5733584
      • 11.3.1.3. Recent Developments and Future Outlook
    • 11.3.2. Sanofi
      • 11.3.2.1. Company Overview
      • 11.3.2.2. Next Generation Immune Checkpoint Therapeutics Portfolio
        • 11.3.2.2.1. Sarclisa
      • 11.3.2.3. Recent Developments and Future Outlook
  • 11.4. Immune Checkpoint Inhibitors Offered by Drug Developers Based in Asia-Pacific
    • 11.4.1. Aurigene Oncology
      • 11.4.1.1. Company Overview
      • 11.4.1.2. Next Generation Immune Checkpoint Therapeutics Portfolio
        • 11.4.1.2.1. Cenopodlin
      • 11.4.1.3. Recent Developments and Future Outlook
    • 11.4.2. Ono Pharmaceutical
      • 11.4.2.1. Company Overview
      • 11.4.2.2. Next Generation Immune Checkpoint Therapeutics Portfolio
        • 11.4.2.2.1. ONO-4482
      • 11.4.2.3. Recent Developments and Future Outlook
    • 11.4.3. Takeda Pharmaceutical
      • 11.4.3.1. Company Overview
      • 11.4.3.2. Next Generation Immune Checkpoint Therapeutics Portfolio
        • 11.4.3.2.1. Mezagitamab
      • 11.4.3.3. Recent Developments and Future Outlook

12. MARKET IMPACT ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Market Drivers
  • 12.3. Market Restraints
  • 12.4. Market Opportunities
  • 12.5. Market Challenges
  • 12.6. Conclusion

13. GLOBAL NEXT GENERATION IMMUNE CHECKPOINT INHIBITORS MARKET

  • 13.1. Chapter Overview
  • 13.2. Key Assumptions and Methodology
  • 13.3. Global Next Generation Immune Checkpoint Inhibitors Market, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 13.4. Multivariate Scenario Analysis
    • 13.4.1. Conservative Scenario
    • 13.4.2. Optimistic Scenario
  • 13.5. Key Market Segmentations

14. NEXT GENERATION IMMUNE CHECKPOINT INHIBITORS MARKET, BY TARGET IMMUNE CHECKPOINT

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Methodology
  • 14.3. Next Generation Immune Checkpoint Inhibitors Market: Distribution by Target Immune Checkpoint
    • 14.3.1. Next Generation Immune Checkpoint Inhibitors Market for CD38, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 14.3.2. Next Generation Immune Checkpoint Inhibitors Market for B7-H3, Forecasted Estimates (till 2035)
    • 14.3.3. Next Generation Immune Checkpoint Inhibitors Market for TIGIT, Forecasted Estimates (till 2035)
    • 14.3.4. Next Generation Immune Checkpoint Inhibitors Market for LAG-3, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 14.3.5. Next Generation Immune Checkpoint Inhibitors Market for CD73, Forecasted Estimates (till 2035)
  • 14.4. Data Triangulation and Validation

15. NEXT GENERATION IMMUNE CHECKPOINT INHIBITORS MARKET, BY TARGET DISEASE INDICATIONS

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Methodology
  • 15.3. Next Generation Immune Checkpoint Inhibitors Market: Distribution by Target Disease Indications
    • 15.3.1. Next Generation Immune Checkpoint Inhibitors Market for Multiple Myeloma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 15.3.2. Next Generation Immune Checkpoint Inhibitors Market for Lung Cancer, Forecasted Estimates (Till 2035)
    • 15.3.3. Next Generation Immune Checkpoint Inhibitors Market for Immune Thrombocytopenia, Forecasted Estimates (Till 2035)
    • 15.3.4. Next Generation Immune Checkpoint Inhibitors Market for Melanoma, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 15.3.4. Next Generation Immune Checkpoint Inhibitors Market for Prostate Cancer, Forecasted Estimates (Till 2035)
    • 15.3.6. Next Generation Immune Checkpoint Inhibitors Market for Esophageal Cancer, Forecasted Estimates (Till 2035)
    • 15.3.7. Next Generation Immune Checkpoint Inhibitors Market for Light Chain Amyloidosis, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 15.3.8. Next Generation Immune Checkpoint Inhibitors Market for Pancreatic Cancer, Forecasted Estimates (Till 2035)
  • 15.4. Data Triangulation and Validation

16. NEXT GENERATION IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE OF MOLECULE

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Methodology
  • 16.3. Next Generation Immune Checkpoint Inhibitors Market: Distribution by Type of Molecule
    • 16.3.1. Next Generation Immune Checkpoint Inhibitors Market for Biologics, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 16.3.2. Next Generation Immune Checkpoint Inhibitors Market for Small Molecules, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 16.4. Data Triangulation and Validation

17. NEXT GENERATION IMMUNE CHECKPOINT INHIBITORS MARKET, BY GEOGRAPHICAL REGIONS

  • 17.1. Chapter Overview
  • 17.2. Assumptions and Methodology
  • 17.3. Next Generation Immune Checkpoint Inhibitors Market: Distribution by Geographical Regions
    • 17.3.1. Next Generation Immune Checkpoint Inhibitors Market in North America, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
      • 17.3.1.1. Next Generation Immune Checkpoint Inhibitors Market in the US, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
      • 17.3.1.2. Next Generation Immune Checkpoint Inhibitors Market in Canada, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 17.3.2. Next Generation Immune Checkpoint Inhibitors Market in Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
      • 17.3.2.1. Next Generation Immune Checkpoint Inhibitors Market in EU5, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
      • 17.3.2.2. Next Generation Immune Checkpoint Inhibitors Market in the Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 17.3.3. Next Generation Immune Checkpoint Inhibitors Market in Asia-Pacific and Rest of the World, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
      • 17.3.3.1. Next Generation Immune Checkpoint Inhibitors Market in China, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
      • 17.3.3.2. Next Generation Immune Checkpoint Inhibitors Market in Japan, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
      • 17.3.3.3. Next Generation Immune Checkpoint Inhibitors Market in Brazil, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
      • 17.3.3.4. Next Generation Immune Checkpoint Inhibitors Market in Australia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
      • 17.3.3.5. Next Generation Immune Checkpoint Inhibitors Market in South Korea, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
      • 17.3.3.6. Next Generation Immune Checkpoint Inhibitors Market in India, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
      • 17.3.3.7. Next Generation Immune Checkpoint Inhibitors Market in Argentina, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
      • 17.3.3.8. Next Generation Immune Checkpoint Inhibitors Market in Israel, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
      • 17.3.3.9. Next Generation Immune Checkpoint Inhibitors Market in Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 17.4. Data Triangulation and Validation

18. NEXT GENERATION IMMUNE CHECKPOINT INHIBITORS MARKET, BY LEADING PLAYERS

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Next Generation Immune Checkpoint Inhibitors Market: Distribution by Leading Players
    • 18.3.1. Next Generation Immune Checkpoint Inhibitors Market for Arcus Biosciences, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.2. Next Generation Immune Checkpoint Inhibitors Market for Daiichi Sankyo, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.3. Next Generation Immune Checkpoint Inhibitors Market for GlaxoSmithKline, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.4. Next Generation Immune Checkpoint Inhibitors Market for Johnson and Johnson, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.5. Next Generation Immune Checkpoint Inhibitors Market for ONO Pharmaceuticals, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.6. Next Generation Immune Checkpoint Inhibitors Market for Regeneron Pharmaceuticals, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.7. Next Generation Immune Checkpoint Inhibitors Market for Sanofi, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
    • 18.3.8. Next Generation Immune Checkpoint Inhibitors Market for Takeda, Historical Trends (Since 2022) and Forecasted Estimates (Till 2035)
  • 18.4. Data Triangulation and Validation

19. NEXT GENERATION IMMUNE CHECKPOINT INHIBITORS MARKET: SALES FORECAST OF THERAPIES

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. Next Generation Immune Checkpoint Inhibitors Market: Sales Forecast of Therapies
    • 19.3.1. Darzalex: Sales Forecast (USD Million)
    • 19.3.2. Sarclisa: Sales Forecast (USD Million)
    • 19.3.3. ONO-4482: Sales Forecast (USD Million)
    • 19.3.4. Ifinatamab Deruxtecan / MK-2400: Sales Forecast (USD Million)
    • 19.3.5. GSK5764227: Sales Forecast (USD Million)
    • 19.3.6. Mezagitamab (TAK-079): Sales Forecast (USD Million)
    • 19.3.7. Fianlimab: Sales Forecast (USD Million)
    • 19.3.8. Quemliclustat: Sales Forecast (USD Million)
    • 19.3.9. Domvanalimab: Sales Forecast (USD Million)
  • 19.4. Data Triangulation and Validation

20. CONCLUDING REMARKS

21. EXECUTIVE INSIGHTS

  • 21.1. Chapter Overview
  • 21.2. Percheron Therapeutics
    • 21.2.1 Company Snapshot
    • 21.2.2. Interview Transcript: James Garner (Chief Executive Officer)
  • 21.3. Merck
    • 21.3.1 Company Snapshot
    • 21.3.2. Interview Transcript: Rob Davis (Chief Executive Officer)

22. APPENDIX I: TABULATED DATA

23. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

Show more
Product Code: RA100629

List of Tables

  • Table 6.1 Types of Immunotherapies and Affiliated Mechanisms of Action
  • Table 6.2 First Generation Immune Checkpoint Therapies
  • Table 7.1 Immune Checkpoint Inhibitors: Information on Developer, Drug Name, Target, Generation of Immune Checkpoint Inhibitor and Stage of Development
  • Table 7.2 Immune Checkpoint Inhibitors: Information on Drug Name, Type of Molecule and Route of Administration
  • Table 7.3 Immune Checkpoint Inhibitors: Information on Target Indication, Therapeutic Area and Type of Therapy
  • Table 7.4 Immune Checkpoint Inhibitors: Information on Drug Designations
  • Table 7.5 Immune Checkpoint Inhibitors Developers: Information on Year of Establishment, Location of Headquarters (Country / Region) and Company Size
  • Table 8.1 Next Generation Immune Checkpoint Inhibitors: Information on Developer, Drug Name, Target, Generation of Immune Checkpoint Inhibitor and Stage of Development
  • Table 8.2 Next Generation Immune Checkpoint Inhibitors: Information on Drug Name, Type of Molecule and Route of Administration
  • Table 8.3 Next Generation Immune Checkpoint Inhibitors: Information on Target Indication, Therapeutic Area and Type of Therapy
  • Table 8.4 Next Generation Immune Checkpoint Inhibitors: Information on Drug Designations
  • Table 8.5 Next Generation Immune Checkpoint Inhibitors Developers: Information on Year of Establishment, Location of Headquarters (Country / Region) and Company Size
  • Table 8.5 Next Generation Immune Checkpoint Inhibitors Developers: Information on Year of Establishment, Location of Headquarters (Country / Region) and Company Size
  • Table 11.1 Next Generation Immune Checkpoint Inhibitors: List of Drug Developers Profiled
  • Table 11.2 Arcus Biosciences: Company Overview
  • Table 11.3 Drug Profile: Domvanalimab
  • Table 11.4 Drug Profile: Quemliclustat
  • Table 11.5 Arcus Biosciences: Recent Developments and Future Outlook
  • Table 11.6 Genentech: Company Overview
  • Table 11.7 Drug Profile: Tiragolumab
  • Table 11.8 Johnson & Johnson: Company Overview
  • Table 11.9 Drug Profile: Daratumumab
  • Table 11.10 Johnson & Johnson: Recent Developments and Future Outlook
  • Table 11.11 Merck: Company Overview
  • Table 11.12 Drug Profile: Ifinatamab Deruxtecan
  • Table 11.13 Merck: Recent Developments and Future Outlook
  • Table 11.14 NovaBridge Biosciences: Company Overview
  • Table 11.15 Drug Profile: Uliledlimab
  • Table 11.16 NovaBridge Biosciences: Recent Developments and Future Outlook
  • Table 11.17 Regeneron Pharmaceuticals: Company Overview
  • Table 11.18 Drug Profile: FIANLIMAB
  • Table 11.19 Regeneron Pharmaceuticals: Recent Developments and Future Outlook
  • Table11.20 Glaxosmithkline: Company Overview
  • Table11.21 Drug Profile: GSK5764227
  • Table11.22 Drug Profile: GSK5733584
  • Table11.23 Glaxosmithkline: Recent Developments and Future Outlook
  • Table11.24 Sanofi: Company Overview
  • Table11.25 Drug Profile: Sarclisa
  • Table11.26 Sanofi: Recent Developments and Future Outlook
  • Table11.27 Aurigene Oncology: Company Overview
  • Table11.28 Drug Profile: Cenopodlin
  • Table11.29 Ono Pharmaceutical: Company Overview
  • Table11.30 Drug Profile: ONO-4482
  • Table11.31 Takeda Pharmaceutical: Company Overview
  • Table11.32 Drug Profile: Mezagitamab
  • Table 13.1 Next Generation Immune Checkpoint Inhibitors: List of Forecasted Therapies
  • Table 22.1 Immune Checkpoint Inhibitors: Distribution by Generation of Target Immune Checkpoint
  • Table 22.2 Immune Checkpoint Inhibitors: Distribution by Stage of Development
  • Table 22.3 Immune Checkpoint Inhibitors: Analysis Type of Molecule
  • Table 22.4 Immune Checkpoint Inhibitors: Distribution by Route of Administration
  • Table 22.5 Immune Checkpoint Inhibitors: Distribution by Therapeutic Area
  • Table 22.6 Immune Checkpoint Inhibitors: Analysis of Prominent Oncological Indications
  • Table 22.7 Immune Checkpoint Inhibitors: Distribution by Prominent Non-Oncological Indications
  • Table 22.8 Immune Checkpoint Inhibitors: Distribution by Type of Therapy
  • Table 22.9 Immune Checkpoint Inhibitors: Distribution by Drug Designations
  • Table 22.10 Immune Checkpoint Inhibitor Developers: Distribution by Year of Establishment
  • Table 22.11 Immune Checkpoint Inhibitor Developers: Distribution by Company Size
  • Table 22.12 Immune Checkpoint Inhibitor Developers: Distribution by Location of Headquarters (Region)
  • Table 22.13 Immune Checkpoint Inhibitor Developers: Distribution by Location of Headquarters (Country)
  • Table 22.14 Most Active Players: Distribution by Number of Immune Checkpoint Inhibitor Therapies
  • Table 22.15 Most Active Players: Distribution by Prominent Targets
  • Table 22.16 Next Generation Immune Checkpoint Inhibitors: Distribution by Target Immune Checkpoint
  • Table 22.17 Next Generation Immune Checkpoint Inhibitors: Analysis Stage of Development
  • Table 22.18 Next Generation Immune Checkpoint Inhibitors: Distribution by Type of Molecule
  • Table 22.19 Next Generation Immune Checkpoint Inhibitors: Distribution by Route of Administration
  • Table 22.20 Next Generation Immune Checkpoint Inhibitors: Distribution by Therapeutic Area
  • Table 22.21 Next Generation Immune Checkpoint Inhibitors: Distribution by Prominent Oncological Indications
  • Table 22.22 Next Generation Immune Checkpoint Inhibitors: Distribution by Prominent Non-Oncological Indications
  • Table 22.23 Next Generation Immune Checkpoint Inhibitors: Distribution by Type of Therapy
  • Table 22.24 Next Generation Immune Checkpoint Inhibitors: Distribution by Drug Designations
  • Table 22.25 Next Generation Immune Checkpoint Inhibitor Developers: Distribution by Year of Establishment
  • Table 22.26 Next Generation Immune Checkpoint Inhibitor Developers: Distribution by Company Size
  • Table 22.27 Next Generation Immune Checkpoint Inhibitor Developers; Distribution by Location of Headquarters (Region)
  • Table 22.28 Next Generation Immune Checkpoint Inhibitor Developers: Distribution by Location of Headquarters (Country)
  • Table 22.29 Most Active Players: Distribution by Number of Next Generation Immune Checkpoint Inhibitor Therapies
  • Table 22.30 Prominent Next Generation Targets: Distribution by Number of Developers
  • Table 22.31 Clinical Trial Analysis: Distribution by Trial Registration Year, Since Pre-2021
  • Table 22.32 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since Pre-2021
  • Table 22.33 Clinical Trial Analysis: Distribution by Trial Status
  • Table 22.34 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Table 22.35 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 22.36 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Table 22.37 Clinical Trial Analysis: Distribution by Patient Gender
  • Table 22.38 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Table 22.39 Clinical Trial Analysis: Distribution by Type of Allocation
  • Table 22.40 Clinical Trial Analysis: Distribution by Type of Intervention Model
  • Table 22.41 Clinical Trial Analysis: Distribution by Type of Masking
  • Table 22.42 Clinical Trial Analysis: Distribution by Primary Purpose
  • Table 22.43 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 22.44 Most Active Industry Players: Distribution by Number of Registered Trials
  • Table 22.45 Most Active Non-Industry Players: Distribution by Number of Registered Trials
  • Table 22.46 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
  • Table 22.47 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
  • Table 23.48 Global Next Generation Immune Checkpoint Inhibitors Market, Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Table 23.49 Global Next Generation Immune Checkpoint Inhibitors Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
  • Table 22.50 Global Next Generation Immune Checkpoint Inhibitors Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
  • Table 22.51 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Target Immune Checkpoint (USD Million)
  • Table 22.52 Next Generation Immune Checkpoint Inhibitors Market for CD38, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.53 Next Generation Immune Checkpoint Inhibitors Market for B7-H3, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.54 Next Generation Immune Checkpoint Inhibitors Market for TIGIT, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.55 Next Generation Immune Checkpoint Inhibitors Market for LAG-3, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.56 Next Generation Immune Checkpoint Inhibitors Market for CD73, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.57 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Target Disease Indication (USD Million)
  • Table 22.58 Next Generation Immune Checkpoint Inhibitors Market for Multiple Myeloma, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.59 Next Generation Immune Checkpoint Inhibitors Market for Lung Cancer, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.60 Next Generation Immune Checkpoint Inhibitors Market for Immune Thrombocytopenia, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.61 Next Generation Immune Checkpoint Inhibitors Market for Melanoma, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.62 Next Generation Immune Checkpoint Inhibitors Market for Prostate Cancer, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.63 Next Generation Immune Checkpoint Inhibitors Market for Esophageal Cancer, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.64 Next Generation Immune Checkpoint Inhibitors Market for Light Chain Amyloidosis, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.65 Next Generation Immune Checkpoint Inhibitors Market for Pancreatic Cancer, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.66 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Type of Molecule (USD Million)
  • Table 22.67 Next Generation Immune Checkpoint Inhibitors Market for Biologics, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.68 Next Generation Immune Checkpoint Inhibitors Market for Small Molecules, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.69 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Geographical Regions (USD Million)
  • Table 22.70 Next Generation Immune Checkpoint Inhibitors Market for North America, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.71 Next Generation Immune Checkpoint Inhibitors Market for the US, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.72 Next Generation Immune Checkpoint Inhibitors Market for Canada, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.71 Next Generation Immune Checkpoint Inhibitors Market for Europe, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.73 Next Generation Immune Checkpoint Inhibitors Market for EU5, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.74 Next Generation Immune Checkpoint Inhibitors Market for Rest of Europe, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.75 Next Generation Immune Checkpoint Inhibitors Market for Asia-Pacific and Rest of the World, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.76 Next Generation Immune Checkpoint Inhibitors Market for China, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.77 Next Generation Immune Checkpoint Inhibitors Market for Japan, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.78 Next Generation Immune Checkpoint Inhibitors Market for Brazil, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.79 Next Generation Immune Checkpoint Inhibitors Market for Australia, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.80 Next Generation Immune Checkpoint Inhibitors Market for South Korea, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.81 Next Generation Immune Checkpoint Inhibitors Market for India, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.82 Next Generation Immune Checkpoint Inhibitors Market for Argentina, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.83 Next Generation Immune Checkpoint Inhibitors Market for Israel, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.84 Next Generation Immune Checkpoint Inhibitors Market for Saudi Arabia, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.85 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Leading Players (USD Million)
  • Table 22.86 Next Generation Immune Checkpoint Inhibitors Market for Johnson and Johnson, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.87 Next Generation Immune Checkpoint Inhibitors Market for Daichii Sankyo, Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.88 Next Generation Immune Checkpoint Inhibitors Market for Arcus Biosciences, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.89 Next Generation Immune Checkpoint Inhibitors Market for GlaxoSmithKline, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.90 Next Generation Immune Checkpoint Inhibitors Market for Takeda, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.91 Next Generation Immune Checkpoint Inhibitors Market for Sanofi, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.92 Next Generation Immune Checkpoint Inhibitors Market for Regeneron Pharmaceuticals, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.93 Next Generation Immune Checkpoint Inhibitors Market for ONO Pharmaceuticals, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.94 Next Generation Immune Checkpoint Inhibitors Market: Sales Forecast for Therapies, 2022, 2026 and 2035 (USD Million)
  • Table 22.95 Next Generation Immune Checkpoint Inhibitors Market for Darzalex, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.96 Next Generation Immune Checkpoint Inhibitors Market for Sarclisa, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.97 Next Generation Immune Checkpoint Inhibitors Market for ONO-4882, Historical Trends (Since 2022) and Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.98 Next Generation Immune Checkpoint Inhibitors Market for Ifinatamab Deruxtecan / MK-2400, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.99 Next Generation Immune Checkpoint Inhibitors Market for GSK5764227, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.100 Next Generation Immune Checkpoint Inhibitors Market for Mezagitamab (TAK-079), Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.101 Next Generation Immune Checkpoint Inhibitors Market for Fianlimab, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.102 Next Generation Immune Checkpoint Inhibitors Market for Quemliclustat, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 22.103 Next Generation Immune Checkpoint Inhibitors Market for Domvanalimab, Forecasted Estimates (till 2035), Conservative, Base and Optimistic Scenarios (USD Million)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Data Sources for Secondary Research
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 3.1 Market Dynamics: Forecast Methodology
  • Figure 3.2 Market Dynamics: Market Assessment Framework
  • Figure 4.1 Lessons Learnt from Past Recessions
  • Figure 5.1 Executive Summary: Market Landscape
  • Figure 5.2 Executive Summary: Market Trends
  • Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 6.1 Global Age-Standardized Incidence Rates for Cancer in Top 5 Countries, 2025
  • Figure 6.2 Mechanisms of Immunotherapies
  • Figure 6.3 Immune Checkpoint Therapies
  • Figure 7.1 Immune Checkpoint Inhibitors: Distribution by Generation of Target Immune Checkpoint
  • Figure 7.2 Immune Checkpoint Inhibitors: Distribution by Stage of Development
  • Figure 7.3 Immune Checkpoint Inhibitors: Distribution by Type of Molecule
  • Figure 7.4 Immune Checkpoint Inhibitors: Distribution by Route of Administration
  • Figure 7.5 Immune Checkpoint Inhibitors: Distribution by Therapeutic Area
  • Figure 7.6 Immune Checkpoint Inhibitors: Distribution by Prominent Oncological Indications
  • Figure 7.7 Immune Checkpoint Inhibitors: Distribution by Prominent Non-Oncological Indications
  • Figure 7.8 Immune Checkpoint Inhibitors: Distribution by Type of Therapy
  • Figure 7.9 Immune Checkpoint Inhibitors: Distribution by Drug Designations
  • Figure 7.10 Immune Checkpoint Inhibitor Developers: Distribution by Year of Establishment
  • Figure 7.11 Immune Checkpoint Inhibitor Developers: Distribution by Company Size
  • Figure 7.12 Immune Checkpoint Inhibitor Developers: Distribution by Location of Headquarters (Region)
  • Figure 7.13 Immune Checkpoint Inhibitor Developers: Distribution by Location of Headquarters (Country)
  • Figure 7.14 Most Active Players: Distribution by Number of Immune Checkpoint Inhibitor Therapies Developed
  • Figure 7.15 Prominent Targets: Distribution by Number of Developers
  • Figure 8.1 Next Generation Immune Checkpoint Inhibitors: Distribution by Target Immune Checkpoint
  • Figure 8.2 Next Generation Immune Checkpoint Inhibitors: Distribution by Stage of Development
  • Figure 8.3 Next Generation Immune Checkpoint Inhibitors: Distribution by Type of Molecule
  • Figure 8.4 Next Generation Immune Checkpoint Inhibitors: Distribution by Route of Administration
  • Figure 8.5 Next Generation Immune Checkpoint Inhibitors: Distribution by Therapeutic Area
  • Figure 8.6 Next Generation Immune Checkpoint Inhibitors: Distribution by Prominent Oncological Indications
  • Figure 8.7 Next Generation Immune Checkpoint Inhibitors: Distribution by Prominent Non-Oncological Indications
  • Figure 8.8 Next Generation Immune Checkpoint Inhibitors: Distribution by Type of Therapy
  • Figure 8.9 Next Generation Immune Checkpoint Inhibitors: Distribution Drug Designations
  • Figure 8.10 Next Generation Immune Checkpoint Inhibitor Developers: Distribution by Year of Establishment
  • Figure 8.11 Next Generation Immune Checkpoint Inhibitor Developers: Distribution by Company Size
  • Figure 8.12 Next Generation Immune Checkpoint Inhibitor Developers: Distribution by Location of Headquarters (Region)
  • Figure 8.13 Next Generation Immune Checkpoint Inhibitor Developers: Distribution by Location of Headquarters (Country)
  • Figure 8.14 Most Active Players: Distribution by Number of Next Generation Immune Checkpoint Inhibitor Therapies Developed
  • Figure 8.15 Prominent Next Generation Targets: Distribution by Number of Developers
  • Figure 9.1 Target Competitiveness Analysis: 3D Bubble Analysis for Next Generation Immune Checkpoint Inhibitor Targets
  • Figure 9.2 Next Generation Immune Checkpoint Therapies: Spider Web Analysis
  • Figure 10.1 Clinical Trial Analysis: Distribution by Trial Registration Year, Since Pre-2021
  • Figure 10.2 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since Pre-2021
  • Figure 10.3 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 10.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Figure 10.5 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 10.6 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Figure 10.7 Clinical Trial Analysis: Distribution by Patient Gender
  • Figure 10.8 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Figure 10.9 Clinical Trial Analysis: Distribution by Type of Allocation
  • Figure 10.10 Clinical Trial Analysis: Distribution by Type of Intervention Model
  • Figure 10.11 Clinical Trial Analysis: Distribution by Type of Masking
  • Figure 10.12 Clinical Trial Analysis: Distribution by Trial Purpose
  • Figure 10.13 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 10.14 Most Active Industry Players: Distribution by Number of Registered Trials
  • Figure 10.15 Most Active Non-Industry Players: Distribution by Number of Registered Trials
  • Figure 10.16 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
  • Figure 10.17 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
  • Figure 10.18 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status and Geography
  • Figure 13.1 Global Next Generation Immune Checkpoint Inhibitors Market, Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 13.2 Global Next Generation Immune Checkpoint Inhibitors Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
  • Figure 13.3 Global Next Generation Immune Checkpoint Inhibitors Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
  • Figure 14.1 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Target Immune Checkpoint
  • Figure 14.2 Next Generation Immune Checkpoint Inhibitors Market for CD38: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 14.3 Next Generation Immune Checkpoint Inhibitors Market for B7-H3: Forecasted Estimates (till 2035) (USD Million)
  • Figure 14.4 Next Generation Immune Checkpoint Inhibitors Market for TIGIT: Forecasted Estimates (till 2035) (USD Million)
  • Figure 14.5 Next Generation Immune Checkpoint Inhibitors Market for LAG-3: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 14.6 Next Generation Immune Checkpoint Inhibitors Market for CD73: Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.1 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Target Disease Indication
  • Figure 15.2 Next Generation Immune Checkpoint Inhibitors Market for Multiple Myeloma: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.3 Next Generation Immune Checkpoint Inhibitors Market for Lung Cancer: Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.4 Next Generation Immune Checkpoint Inhibitors Market for Immune Thrombocytopenia: Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.5 Next Generation Immune Checkpoint Inhibitors Market for Melanoma: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.6 Next Generation Immune Checkpoint Inhibitors Market for Prostate Cancer: Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.7 Next Generation Immune Checkpoint Inhibitors Market for Esophageal Cancer: Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.8 Next Generation Immune Checkpoint Inhibitors Market for Light Chain Amyloidosis: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 15.9 Next Generation Immune Checkpoint Inhibitors Market for Pancreatic Cancer: Forecasted Estimates (till 2035) (USD Million)
  • Figure 16.1 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Type of Molecule
  • Figure 16.2 Next Generation Immune Checkpoint Inhibitors Market for Biologics: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 16.3 Next Generation Immune Checkpoint Inhibitors Market for Small Molecules: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.1 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Geographical Regions
  • Figure 17.2 Next Generation Immune Checkpoint Inhibitors Market in North America: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.3 Next Generation Immune Checkpoint Inhibitors Market in United States: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.4 Next Generation Immune Checkpoint Inhibitors Market in Canada: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.5 Next Generation Immune Checkpoint Inhibitors Market in Europe: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.6 Next Generation Immune Checkpoint Inhibitors Market in EU5: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.7 Next Generation Immune Checkpoint Inhibitors Market in Rest of Europe: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.8 Next Generation Immune Checkpoint Inhibitors Market in Asia-Pacific and Rest of the World: Historical trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.9 Next Generation Immune Checkpoint Inhibitors Market in China: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.10 Next Generation Immune Checkpoint Inhibitors Market in Japan: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.11 Next Generation Immune Checkpoint Inhibitors Market in Brazil: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.12 Next Generation Immune Checkpoint Inhibitors Market in Australia: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.13 Next Generation Immune Checkpoint Inhibitors Market in South Korea: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.14 Next Generation Immune Checkpoint Inhibitors Market in India: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.15 Next Generation Immune Checkpoint Inhibitors Market in Aregntina: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.16 Next Generation Immune Checkpoint Inhibitors Market in Israel: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 17.17 Next Generation Immune Checkpoint Inhibitors Market in Saudi Arabia: Historical Trends (Since 2022) and Forecasted Estimates (till 2035) (USD Million)
  • Figure 18.1 Next Generation Immune Checkpoint Inhibitors Market: Distribution by Sales Forecast of Leading Players
  • Figure 18.2 Next Generation Immune Checkpoint Inhibitors Market: Johnson and Johnson Sales Forecast, 2022-2035 (USD Million)
  • Figure 18.3 Next Generation Immune Checkpoint Inhibitors Market: Daiichi Sankyo Sales Forecast, till 2035 (USD Million)
  • Figure 18.4 Next Generation Immune Checkpoint Inhibitors Market: Arcus Biosciences Sales Forecast, till 2035 (USD Million)
  • Figure 18.5 Next Generation Immune Checkpoint Inhibitors Market: GlaxoSmithKline Sales Forecast, till 2035 (USD Million)
  • Figure 18.6 Next Generation Immune Checkpoint Inhibitors Market: Takeda Sales Forecast, till 2035 (USD Million)
  • Figure 18.7 Next Generation Immune Checkpoint Inhibitors Market: Sanofi Sales Forecast, 2022-2035 (USD Million)
  • Figure 18.8 Next Generation Immune Checkpoint Inhibitors Market: Regeneron Pharmaceuticals Sales Forecast, till 2035 (USD Million)
  • Figure 18.9 Next Generation Immune Checkpoint Inhibitors Market: ONO PHARMACEUTICAL Sales Forecast, 2022-2035 (USD Million)
  • Figure 19.1 Next Generation Immune Checkpoint Inhibitors Market: Darzalex Sales Forecast, 2022-2035 (USD Million)
  • Figure 19.2 Next Generation Immune Checkpoint Inhibitors Market: Sarclisa Sales Forecast, 2022-2035 (USD Million)
  • Figure 19.3 Next Generation Immune Checkpoint Inhibitors Market: ONO-4482 Sales Forecast, 2022-2035 (USD Million)
  • Figure 19.4 Next Generation Immune Checkpoint Inhibitors Market: Ifinatamab Deruxtecan / MK-2400 Sales Forecast, till 2035 (USD Million)
  • Figure 19.5 Next Generation Immune Checkpoint Inhibitors Market: GSK5764227 Sales Forecast, till 2035 (USD Million)
  • Figure 19.6 Next Generation Immune Checkpoint Inhibitors Market: Mezagitamab (TAK-079) Sales Forecast, till 2035 (USD Million)
  • Figure 19.7 Next Generation Immune Checkpoint Inhibitors Market: Domvanalimab Sales Forecast, till 2035 (USD Million)
  • Figure 19.8 Next Generation Immune Checkpoint Inhibitors Market: Fianlimab Sales Forecast, till 2035 (USD Million)
  • Figure 19.9 Next Generation Immune Checkpoint Inhibitors Market: Quemliclustat Sakes Forecast, till 2035 (USD Million)
  • Figure 20.1 Concluding Remarks: Immune Checkpoint Inhibitors Market Landscape
  • Figure 20.2 Concluding Remarks: Next Generation Immune Checkpoint Inhibitors Market Landscape
  • Figure 20.3 Concluding Remarks: Clinical Trial Analysis
  • Figure 20.4 Concluding Remarks: Market Sizing and Opportunity Analysis
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!